Results 131 to 140 of about 560,370 (324)

NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence

Cell Death Discovery
Gefitinib is one of the most extensively utilized epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for treating advanced lung adenocarcinoma (LUAD) patients harboring EGFR mutation.
Shuman Zhen, Yunlong Jia, Yan Zhao, Jiali Wang, Boyang Zheng, Tianxu Liu, Yuqing Duan, Wei Lv, Jiaqi Wang, Fan Xu, Yueping Liu, Yi Zhang, Lihua Liu   +12 more
doaj   +1 more source

Simplified model of immunotherapy for glioblastoma multiforme: cancer stem cells hypothesis perspective [PDF]

arXiv
Despite ongoing efforts in cancer research, a fully effective treatment for glioblastoma multiforme (GBM) is still unknown. Since adoptive cell transfer immunotherapy is one of the potential cure candidates, efforts have been made to assess its effectiveness using mathematical modeling.
arxiv  

Approximate Analytical Solution of a Cancer Immunotherapy Model by the Application of Differential Transform and Adomian Decomposition Methods [PDF]

arXiv, 2018
Immunotherapy plays a major role in tumour treatment, in comparison with other methods of dealing with cancer. The Kirschner-Panetta (KP) model of cancer immunotherapy describes the interaction between tumour cells, effector cells and interleukin-2 which are clinically utilized as medical treatment.
arxiv  

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Molecular Cancer Therapeutics, 2017
Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non–small cell lung cancer (NSCLC).
A. Goodman, S. Kato, L. Bazhenova, S. Patel, G. Frampton, V. Miller, P. Stephens, G. Daniels, R. Kurzrock   +8 more
semanticscholar   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Melanoma immunotherapy

Oncoscience, 2015
ispartof: Oncoscience vol:2 issue:10 pages:845 ...
Garg, Abhishek, Dudek-Peric, Aleksandra M., Agostinis, Patrizia   +2 more
openaire   +3 more sources

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Journal of Immunotherapy for Cancer, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
I. Puzanov, A. Diab, K. Abdallah, C. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. Lacouture, N. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. Silk, D. Skondra, M. Suarez‐Almazor, Y. Wang, K. Wiley, H. Kaufman, M. Ernstoff, Jeff Deborah Stephanie Joan Janie Daniel David Ion Rena Anderson Arrindell Andrews Ballesteros Boyer Chen , J. Anderson, Deborah Arrindell, S. Andrews, J. Ballesteros, J. Boyer, Daniel S Chen, David Chonzi, I. Cotarla, R. Cunha, M. Davies, M. Dawson, A. Dicker, L. Eifler, Andrew D. Ferguson, C. Ferlini, S. Frankel, W. Go, Celestine G. Gochett, J. Goldberg, P. Goncalves, T. Goswami, Nancy C. Gregory, J. Gulley, V. Hayreh, Nicole Helie, William C. Holmes, J. hsu, R. Ibrahim, C. Larocca, K. Lehman, S. Ley-Acosta, O. Lambotte, J. Luke, J. Mcclure, E. Michelon, Mary C. Nakamura, K. Patel, B. Piperdi, Z. Rasheed, D. Reshef, J. Riemer, C. Robert, M. Sarkeshik, Ann Saylors, J. Schreiber, K. Shafer-Weaver, W. Sharfman, E. Sharon, R. Sherry, C. Simonson, C. Thomas, John A Thompson, E. Trehu, D. Tresnan, M. Turner, Darshan Wariabharaj, I. Waxman, L. Wood, Lin Zhang, P. Zheng   +81 more
semanticscholar   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

A Dual Approach for Positive T-S Fuzzy Controller Design and Its Application to Cancer Treatment Under Immunotherapy and Chemotherapy [PDF]

arXiv, 2019
This study proposes an effective positive control design strategy for cancer treatment by resorting to the combination of immunotherapy and chemotherapy. The treatment objective is to transfer the initial number of tumor cells and immune-competent cells from the malignant region into the region of benign growth where the immune system can inhibit tumor
arxiv  

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Annals of Oncology, 2018
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive ...
T. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S. Quezada, A. Stenzinger, Solange Peters   +6 more
semanticscholar   +1 more source